top of page
CaliciX™ Max 30 mg | Severe feline calicivirus (FCV) capsules
CaliciX™ Max is a high-dose oral antiviral for cats with severe, refractory or high-viral-load feline calicivirus (FCV), where the standard 15 mg strength has not been enough. Each capsule contains 30 mg of EIDD-1931, the active metabolite of molnupiravir.
 
It is used under veterinary supervision for cats that need greater antiviral exposure, judged on body weight, disease severity and how the cat has responded so far.
 
Severe oral and oropharyngeal disease
  • Severe feline chronic gingivostomatitis (FCGS)
  • Caudal stomatitis with extensive inflammation
  • Ulcerative stomatitis unresponsive to dental extraction
  • Viral glossitis with deep lingual ulceration
  • Multifocal buccal, labial and palatal ulcers
 
These cases present with intense oral pain, heavy drooling, difficulty eating and swallowing, weight loss and wasting, and persistent halitosis or oral bleeding.
 
Virulent systemic feline calicivirus
  • Virulent systemic feline calicivirus (VS-FCV)
  • Fever and marked lethargy
  • Facial and limb oedema
  • Lameness
  • Pulmonary involvement and pneumonia
  • Raised hepatic and pancreatic enzymes
  • A rapidly worsening inflammatory response
 
Refractory and relapsing cases
  • Continued calicivirus shedding
  • Feline chronic gingivostomatitis that remains active after extraction
  • Chronic stomatitis relapsing after steroid or immunosuppressant use
  • Larger cats requiring greater antiviral exposure
 
Why the higher strength
Severe calicivirus disease can require higher systemic concentrations to suppress replication quickly and limit viral damage to the mucosa and beyond. The 30 mg format reaches those concentrations with fewer capsules per dose, which improves dosing accuracy and makes the course easier to sustain. It is the step-up option when 15 mg is no longer enough.
 
Before you start
Not every case of stomatitis or gingivitis in cats is caused by feline calicivirus. Have your cat examined before starting. CaliciX™ Max is a high-dose product for severe cases; mild to moderate disease should use CaliciX™ 15 mg.

CaliciX™ Max 30 mg | Severe feline calicivirus (FCV) capsules

‏249.00 د.إ.‏السعر

  • 1. Active ingredient

    EIDD-1931 (β-D-N4-hydroxycytidine) 30 mg per capsule Active metabolite of molnupiravir (EIDD-2801) Mutagenic nucleoside analogue acting on RNA-dependent RNA polymerase (RdRp) Pharmacologically equivalent to approximately 133 mg of molnupiravir

    2. Therapeutic class

    • Direct-acting antiviral (DAA)
    • Broad-spectrum RNA virus inhibitor
    • Viral error catastrophe inducer

    3. Mechanism of action

    EIDD-1931 is phosphorylated intracellularly to its triphosphate form and incorporated into viral RNA during replication. Transition mutations accumulate, viral genome integrity is lost, and production of infectious virus is suppressed. The mechanism is host-independent and does not act through viral proteases, which is thought to limit the development of resistance.

    4. Indications

    Severe or refractory disease associated with feline calicivirus.

    Severe oral disease

    • Severe feline chronic gingivostomatitis (FCGS)
    • Caudal stomatitis with extensive inflammation
    • Ulcerative stomatitis unresponsive to extraction
    • Viral glossitis with deep lingual ulceration
    • Multifocal buccal, labial and palatal ulcers

    Virulent systemic feline calicivirus

    • Virulent systemic feline calicivirus (VS-FCV)
    • Fever and lethargy
    • Facial and limb oedema
    • Lameness
    • Pneumonia and respiratory deterioration
    • Inflammatory changes in the liver and pancreas

    Refractory and high-risk cases

    • Feline chronic gingivostomatitis remaining active after extraction
    • Continued calicivirus shedding
    • Cases relapsing after steroid or immunosuppressant use
    • Larger cats requiring greater antiviral exposure

    5. Clinical signs addressed

    Intense oral pain, drooling, difficulty swallowing and food refusal, oral bleeding and ulceration, halitosis, weight loss and wasting, fever and systemic inflammation.

    6. Dosage and administration

    • Route: oral
    • Frequency: twice daily, every 12 hours
    • High-dose range: above 6 mg/kg, under veterinary direction

    7. Pharmacokinetics

    • Good oral bioavailability
    • Rapid systemic absorption
    • Intracellular activation independent of host enzymes
    • Distribution into oral mucosa, salivary tissue and sites of inflammation
    • Stable exposure without dependence on prodrug conversion

    Formal feline pharmacokinetic studies are ongoing. Dosing rests on translational data and clinical experience.

    8. Safety

    Contraindications

    • Pregnant queens and cats intended for breeding
    • Cats with a history of hypersensitivity to nucleoside analogues

    Use with caution

    • Cats with hepatic impairment
    • Cats with renal disease, particularly alongside NSAIDs
    • Long-term use beyond 12 weeks without monitoring

    Monitoring

    • CBC every 2 to 4 weeks on prolonged courses
    • ALT/AST where other systemic medication is in use
    • Weight and appetite records

    Possible adverse effects

    • Mild gastrointestinal upset
    • Transient lethargy
    • Dose-dependent effects on long courses

    9. Interactions

    No major CYP-mediated interactions are known. Can be combined with analgesics such as buprenorphine, NSAIDs under renal monitoring, antibiotics for secondary infection, and dental care.

    10. Regulatory status

    This product is not licensed for use in cats. It is intended for off-label veterinary use under professional supervision and requires informed owner consent.

    11. Storage

    Store below 25 °C, protected from moisture and light, in the original packaging until use.

لا توجد مراجعات حتى الآنشارك أفكارك. كن أول من يترك مراجعة.
bottom of page